Nanalysis Scientific Corp (NSCI)

Nanalysis Announces First Quarter 2026 ResultsMay 20, 2026 4:51 PM
PR Newswire (US) Reports Quarterly Revenue of $10.7 Million and Adjusted EBITDA of $292 ThousandCALGARY, AB, May 20, 2026 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial and research applications, announces its financial results for the first quarter ending March 31, 2026. Chief Executive Officer Sean Krakiwsky and Interim Chief Financial Officer Heather Kury will host a conference call at 10 A.M. Eastern Time tomorrow to discuss the results. All interested parties are invited to join the call through the details provided below. All dollar figures in this press release are in thousands of Canadian dollars, except per share amounts or unless otherwise stated.   The Company reported first quarter revenue of $10.7 million, consistent with both the prior quarter and the comparative period in 2025. The Company also delivered Adjusted EBITDA of $292 thousand, continuing its trend of positive EBITDA, and representing an increase of $112 thousand over the comparative period in 2025."We are encouraged by the operational progress made during the first quarter, particularly within our Security Services segment where margin performance improved meaningfully year-over year," said Sean Krakiwsky, Founder and CEO of Nanalysis. "While scientific equipment purchasing activity continues to experience longer sales cycles in certain markets, we believe the actions taken throughout 2025 to streamline operations, strengthen sales execution and improve efficiency are beginning to positively impact the business.  We remain focused on disciplined execution, operational efficiency, and positioning the Company for improved performance through the balance of 2026.Financial highlights for the three months ended March 31, 2026:

Three months ended March 31($000's) 
20262025Change $Change %Product sales
2,1793,687(1,508)-41 %Security services revenue
5,9045,02388118 %Flow-through inventory revenue
2,5841,88470037 %Total sales and revenue
10,66710,594731 %





Gross margin percentage - product sales
58 %66 %-8 %
Gross margin percentage - service revenue
19 %6 %13 %






Adjusted EBITDA
29218011262 %Net loss
(1,281)(1,307)262 %For the three months ending March 31, 2026, the Company reported consolidated revenue of $10,667, an increase of $73 or 1% from the comparative period in 2025. While there was a decline in product revenue due to lower NMR benchtop sales and the termination of the third-party equipment sales contracts, security services revenue increased primarily due to higher levels of project-related work associated with the Airport Security Maintenance Business.Gross margin percentage for product sales for the three months ended March 31, 2026, was 58%, versus 66% from the comparative period in 2025.  The decrease was primarily due to changes in product mix following the termination of the third-party equipment sales contracts.Gross margin percentage for security services for the three months ended March 31, 2026, was significantly improved at 19% versus 6% from the comparative period in 2025. This increase in margin was driven by operational efficiencies, including enhanced logistics processes and more effective management of overtime and on-call hours, as well as higher levels of project-related service activity. Management believes the operational improvements implemented in 2025 position the segment for continued margin improvement through 2026.The Company recorded Adjusted EBITDA of $292 for the three months ended March 31, 2026. This represents an increase of $112 over Adjusted EBITDA of $180 for the three months ended March 31, 2025. This was primarily the result of an increase in services margin and lower spending in sales and marketing expenses and general and administrative expenses, offset by lower product sales.Net loss was $1,281 for the three months ended March 31, 2026, which is an improvement of $26 from the comparative period in 2025. The decrease in net loss for the three months ended March 31, 2026, was due to improved business margins in 2026.Quarterly Trend:($000's) 
Q1 2026Q4 2025Q3 2025Q2 2025Product sales
2,1794,1332,7192,902Security services revenue
5,9045,5635,9435,617Flow-through parts revenue
2,5849806231,057Total revenue
10,66710,6769,2859,576





Adjusted EBITDA
2921,187(2)(462)





Normalized net loss
(1,281)(729)(1,500)(2,122)In Q1 2026, product sales decreased by $1,954 from Q4 2025 due to normal seasonality and softer benchtop NMR demand in certain markets. This was partially offset by an increase in Security Services revenue driven by higher project-related activity associated with the Airport Security Maintenance Business.Recent strategic and operational highlights include:Debt Repayment: Following completion of the January 2026 equity financing, the Company repaid approximately $2.1 million of its ATB Term Loan and $1.3 million outstanding under its ATB Line of Credit.Improved Services Margin: The Company continued to improve operating performance within its Security Services segment through operational efficiency initiatives and increased levels of project-related work.Sales and Marketing Team Strengthening: As part of its strategy to strengthen and restore European sales activity, the Company materially expanded its European-based sales presence during the quarter and increased focus on its international distributor network.  Distributor-led sales represented ~45% of benchtop NMR sales in Q1 2026. Management expects these investments to support improved sales activity in the second half of 2026.Board of Directors Transition: The Company announced earlier this month that it had appointed three new directors. These new directors bring additional experience in technology commercialization, operational scaling, capital markets and public company governance.  In connection with these appointments Martin Burien and Jennifer Stubbs have stepped down.Continuous Improvement Initiatives: The Company continued executing operational efficiency and cost optimization initiatives during the quarter, including organizational streamlining and prioritization of research and development activities.  These initiatives contributed to lower operating expenses and improved financial performance during the period.Outlook"Our outlook has not changed, and we continue to expect improved operational performance through 2026." said Mr. Krakiwsky. "We believe the actions taken over the past year to strengthen our operational efficiency and invest in customer and distributor relationships are positioning the Company for improved financial performance over time. While macroeconomic conditions continue to impact purchasing timelines in the Scientific Equipment segment, we remain focused on disciplined execution and long-term value creation across both operating segments.Conference Call:Thursday May 21st, 10am ESTInvestors interested in participating in the live call can join through Zoom. Details provided below.https://us02web.zoom.us/j/87624958529?pwd=FxTQ2xf1geEDJ3svrWXYSiNBZ7rJ5g.1Meeting ID: 876 2495 8529
Passcode: 351966One tap mobile
+16699006833,,87624958529#,,,,*351966# US (San Jose)
+16892781000,,87624958529#,,,,*351966# USThe webcast will be archived on the Company's investor relations webpage for at least 90 days.Non-IFRS and Supplementary Financial MeasuresThe Company prepares and reports its consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, as adopted by the Canadian Accounting Standards Board ("IFRS"). However, the press release may make reference to certain non-IFRS measures includes key performance indicators used by management. These measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under IFRSThe ?Company uses Adjusted Earnings Before Interest, Tax, Depreciation and Amortization ("Adjusted EBITDA"), which may be calculated ?differently by other companies. This non-IFRS measure is used to provide investors a supplemental measure of the Company's operating performance and liquidity and thus highlight trends in the Company's ?business that may not otherwise be apparent when relying solely on IFRS measures. The Company also ?believes that securities analysts, investors and other interested parties frequently use non-IFRS measures ?in the evaluation of companies in similar industries.Adjusted EBITDA
 Three months ended March 31 ($000's) 20262025 ($) Change Net loss(1,281)(1,307)26Depreciation and amortization expense888924(36)Finance expense35432727Stock-based compensation63131(68)Other (income) expenses13(138)151Amortization of deferred wages21619026Loss from associate---Impairment of assets---Current income tax expense (recovery)33276Deferred income tax (recovery) expense626(20)Adjusted EBITDA292180112Supplementary Financial Measures The Company may also use supplementary financial measures which are intended to be disclosed on a periodic basis to depict the historical or expected future financial performance, cash position, or cash flow of the Company, are not a non-IFRS measure, and are not presented in the financial statements. The measures as discussed in this press release include:Gross margin, which is defined as either product sales less cost of product sold, or, security services revenue less security services cost; and,Gross margin percentage, which is defined as either (product sales less cost of product sold) divided by product sales or (security services revenue less Security services costs) divided by security services revenueAbout Nanalysis Scientific Corp. (TSXV: NSCI, FRA:1N1)Nanalysis Scientific Corp. develops and manufactures benchtop Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.Notice regarding Forward Looking Statements and Legal DisclaimerThis news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-announces-first-quarter-2026-results-302778198.htmlSOURCE Nanalysis Scientific Corp. Original: Nanalysis Announces First Quarter 2026 Results

Nanalysis Announces First Quarter 2026 Conference CallMay 13, 2026 4:15 PM
PR Newswire (US) Hosting Call at 10am ET on Thursday, May 21stCALGARY, AB, May 13, 2026 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in benchtop NMR instruments and imaging technology and services for industrial and research applications announces that on Wednesday, May 20th 2026, the Company will put out a press release after the market close and Chief Executive Officer Sean Krakiwsky and Interim Chief Financial Officer Heather Kury will host a conference call at 10 A.M. Eastern Time on Thursday, May 21st to discuss the results for the first quarter 2026.  Investors interested in participating in the live call can join through the Zoom details provided below.Join Zoom Meeting
https://us02web.zoom.us/j/87624958529?pwd=FxTQ2xf1geEDJ3svrWXYSiNBZ7rJ5g.1Meeting ID: 876 2495 8529
Passcode: 351966One tap mobile
+16699006833,,87624958529#,,,,*351966# US (San Jose)
+16892781000,,87624958529#,,,,*351966# USThe webcast will be archived on the Company's investor relations webpage for at least 90 days.About Nanalysis Scientific Corp. (TSXV: NSCI, FRA:1N1)Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.Notice regarding Forward Looking Statements and Legal DisclaimerThis news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-announces-first-quarter-2026-conference-call-302771161.htmlSOURCE Nanalysis Scientific Corp. Original: Nanalysis Announces First Quarter 2026 Conference Call

Nanalysis Announces Board Transition and Appointment of Three New DirectorsMay 1, 2026 8:00 AM
PR Newswire (Canada)

CALGARY, AB, May 1, 2026 /CNW/ - Nanalysis Scientific Corp. (the "Company", TSXV: NSCI, FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial and research applications, is pleased to announce the appointment of Jonathan Ladd, Werner Maas, and Steve Feick to its Board of Directors effective May 1, 2026.







Mr. Ladd is an experienced technology executive and former Chief Executive Officer of NovAtel Inc., a Nasdaq-listed GPS technology company acquired by Hexagon AB. He has a track record of scaling global technology businesses and brings extensive experience in capital markets, corporate governance, and strategic execution within advanced technology companies. He currently serves on the following boards: Takemetoit Inc., AgriRobot, Litus Inc., and is an advisor at Tall Grass Ventures. Mr. Ladd earned a bachelor's degree with distinction in engineering and is a member of Tau Beta Pi National Engineering Honor Society.Dr. Maas is a senior executive in the analytical instrumentation sector, having previously served as President of Bruker BioSpin Corporation and currently serving as Chief Executive Officer of Hudson Lab Automation. He brings deep expertise in nuclear magnetic resonance (NMR) technologies, as well as global sales, marketing, and commercialization of scientific instrumentation. Dr. Maas holds a Ph.D. in Chemistry from Radboud University in The Netherlands, as well as several executive management designations from the MIT Sloan School of Management.Mr. Feick is President of Manvest Inc., part of the Mancal Group. He has a track record of developing and growing a portfolio of investments in agriculture, finance, supply chain, infrastructure technology, energy efficiency, and data analytics. As a former entrepreneur, he ensures that his operational and investor experience elevates the growth of the portfolio. He is an experienced investor and brings expertise in capital allocation, governance, and long-term strategic planning across private and public market investments. Mr. Feick holds a Bachelor of Science degree in Chemical Engineering from Queen's University.In connection with these appointments, Martin Burian and Jennifer Stubbs will be stepping down from the Board of Directors, effective May 1, 2026. The Company thanks Mr. Burian and Ms. Stubbs for their contributions and service and wishes them continued success in their future endeavours."On behalf of the Board, I would like to thank Martin and Jennifer for their contributions to Nanalysis and dedicated service to the Company and wish them continued success in their future endeavours." said Sean Krakiwsky, Chief Executive Officer. "We are pleased to welcome Jonathan, Werner, and Steve. Their collective experience across instrumentation, global commercialization, and capital allocation will support the Company as we focus on scaling our core NMR platform and executing on our services growth strategy."About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1)Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.Notice regarding Forward Looking Statements and Legal DisclaimerThis news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-announces-board-transition-and-appointment-of-three-new-directors-302759750.htmlSOURCE Nanalysis Scientific Corp.

Original: Nanalysis Announces Board Transition and Appointment of Three New Directors

https://www.investing.com/news/transcripts/earnings-call-transcript-nanalysis-scientific-misses-q4-2025-revenue-expectations-93CH-4606031

Nanalysis Announces Fourth Quarter and Full Year 2025 ResultsApril 8, 2026 4:15 PM
PR Newswire (US)

Reports Quarterly Revenue of $10.7 Million and Adjusted EBITDA of $1.2 MillionFull Year Revenue of $40.1 Million and Adjusted EBITDA of $903 ThousandCALGARY, AB, April 8, 2026 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial and research applications announces its financial results for the fourth quarter and full year ended December 31, 2025. Chief Executive Officer Sean Krakiwsky and Interim Chief Financial Officer Heather Kury will host a conference call at 10 A.M. Eastern Time tomorrow, April 9th, to discuss the results. All interested parties are invited to join these calls.  All dollar figures in this press release are in thousands of Canadian dollars, except per share amounts or unless otherwise stated.







The Company reported fourth quarter revenue of $10.7 million, representing a decrease of 13% compared to the same period in 2024, and full year revenue of $40.1 million a decrease of 12% year-over-year. Despite lower revenues, the Company delivered Adjusted EBITDA of $1.2 million in the fourth quarter, marking a return to positive quarterly Adjusted EBITDA."We made meaningful progress in 2025 despite a challenging operating environment," said Sean Krakiwsky, Founder and CEO of Nanalysis. "We took decisive actions to strengthen leadership, improve our service operations, and diversify our sales and supply chain strategies. While there is work ahead, these initiatives have improved our operational footing and positioned the business for more consistent execution. As we enter 2026, our focus remains on disciplined execution, improving margins in our service business, and driving growth in our scientific equipment segment. While revenue declined year-over-year, performance improved sequentially through 2025, with the Company returning to positive Adjusted EBITDA in the fourth quarter. This reflects the early impact of operational and strategic changes implemented throughout the year."Financial highlights for the three months ended December 31, 2025:

Three months ended December 31($000's) 
20252024Change $Change %Product sales
4,1335,536(1,403)-25 %Security services revenue
5,5635,602(39)-1 %Flow-through inventory revenue
9801,151(171)-15 %Total sales and revenue
10,67612,289(1,613)-13 %





Gross margin percentage - product sales
56 %60 %-4 %
Gross margin percentage - service revenue
11 %16 %-5 %






Adjusted EBITDA
1,1871,835(648)-35 %Normalized net loss (excludes impairment of assets)  
(729)(400)(329)-82 %Net loss
(729)(7,452)6,72390 %For the three months ended December 31, 2025, the Company reported consolidated revenue of $10,676, a decrease of $1,613 or 13% from the comparative period in 2024.Gross margin percentage for product sales for the three-month period ended December 31, 2025, was 56%, compared to 60% in the prior year period. The decrease was attributable to earlier-period supply chain challenges, which required the Company to utilize higher-cost labour to meet its sales commitments.Security service gross margin percentage for the three-month period ended December 31, 2025,  was 11%, compared to 16% in the prior year period, reflecting both revenue variability and cost structure dynamics associated with the Company's largest contract, as well as the Company's commitment to maintaining a high level of service. The Company is actively working with its customer to address these dynamics and remains confident in reaching a more sustainable and mutually beneficial operating arrangement going forward.Adjusted EBITDA is used by the Company as an approximation for operating cash flows available for reinvestment in the Company and to service financing obligations.  Adjusted EBITDA for the three months ended December 31, 2025, was $1,187, compared to $1,835 in the prior year period.  The decrease reflects prolonged instability in the scientific instrumentation market, which resulted in customer purchasing delays and supply chain disruptions. In response, the Company has diversified its market reach and strengthened its supply chain to improve effectiveness and resilience going forward. The year also included a period of rebuilding within the services segment, with a focus on enhancing the customer experience and improving profitability.Normalized net loss for the three months ended December 31 2025 was $729, compared to $400 in the prior year period. The increase was primarily driven by lower margins. The Company has implemented strategic initiatives to improve profitability across both its scientific equipment and services businesses going forward.Financial highlights for the twelve months ended December 31, 2025:

Twelve months ended December 31($000's) 
20252024Change $Change %Product sales
13,44119,396(5,955)-31 %Security services revenue
22,14621,0101,1365 %Flow-through inventory revenue
4,5445,089(545)-11 %Total sales and revenue
40,13145,495(5,364)-12 %





Gross margin percentage - product sales
57 %53 %4 %
Gross margin percentage - service revenue
10 %12 %-2 %






Adjusted EBITDA
9032,834(1,931)-68 %Normalized net loss (excludes impairment of assets)  
(5,658)(6,287)62910 %Net loss
(5,658)(13,613)7,95558 %The Company reported consolidated revenue of $40,131 for the year, a decrease of $5,364, or 12%, compared to the prior year. This includes $13,441 in product sales, $22,146 in security services revenue, and $4,544 in flow-through inventory revenue.Gross margin percentage on product sales was 57% for the twelve months ended December 31, 2025, compared to 53% in the prior year. The improvement in Benchtop NMR margins was driven by reductions in manufacturing labour implemented in 2023 and 2024, as well as increased process efficiencies.Gross margin percentage on service revenue was 10% for the twelve months ended December 31, 2025, compared to 12% in the prior year.  The Company is implementing strategic measures to stabilize margins going forward, including enhancing customer experience and addressing profitability through improvements to the underlying contract structure.Adjusted EBITDA for the twelve months ended December 31, 2025, was $903 versus an Adjusted EBITDA $2,834 for the same period last year.Normalized net loss for the twelve months ended December 31 2025 was $5,658, compared to $6,287 in the prior year. The improvement was primarily driven by lower depreciation, as an acquired intangible asset was fully impaired in 2024, and the absence of losses from associates following the impairment of the Quad investment in 2024.Quarterly Trend:($000's) 
Q4 2025Q3 2025Q2 2025Q1 2025Product sales
4,1332,7192,9023,687Security services revenue
5,5635,9435,6175,023Flow-through parts revenue  
9806231,0571,884Total revenue
10,6769,2859,57610,594





Adjusted EBITDA
1,187(2)(462)180





Normalized net loss
(729)(1,500)(2,122)(1,307)The Company demonstrated growth in Security services revenue from Q1 2025. Under the current contract structure, revenue is expected to fluctuate modestly from quarter to quarter based on servicing requirements. As the Company enters 2026, it is focused on driving greater stability and revenue growth in this segment through continued delivery of high-quality customer experience and on optimizing contract structure and margins, with the goal of improving gross margins.Normalized net losses continue to improve, in line with the Company's overall operations and reduced depreciation costs.Recent strategic and operational highlights during and after the fourth quarter of 2025 include:Supply chain strengthened through the establishment of relationships with several new vendors for long-lead critical components used in the Company's instruments. This has reduced supply risk and lowered component costs. In response to ongoing geopolitical uncertainty, the Company has also increased inventory levels of key components to support sales and growth targetsGeographic diversification in response to evolving global trade dynamics, including U.S. trade tensions, with an increased emphasis on European markets and international distribution channelsNon-dilutive funding of $1.0 million was awarded in March 2026 under a federal economic development initiative to support the Company's market diversification initiatives and further strengthen its supply chainNon-brokered private placement of $3.4 million was closed in two tranches (December 2025 and January 2026), resulting in a reduction of the Company's term loan from $5.8 million to $3.7 millionCEIA distribution agreement signed in January 2026 for a five-year term, enabling the Company to act as a distributor of CEIA's metal detection equipment in the United States and CanadaAssociate Quad Systems secured a significant contract in November 2025, winning a competitive bid to supply ETH University in Switzerland with a 400 MHz and 500 MHz high-field NMR spectrometer upgradeContinuous improvement initiatives. The Company continued execution of its multi-year cost reduction and operational efficiency program, including headcount reductions and lower R&D and SG&A expenditures, resulting in a meaningful reduction in operating costs. While a continuous improvement culture has been established, the Company expects to maintain disciplined cost optimization through mid-2026Outlook"We are looking forward to a stronger 2026," said Mr. Krakiwsky. "We believe the actions taken over the past year to adapt to changing market conditions and strengthen our operational foundation will begin to translate into improved financial performance. Our continued investment in customer and vendor relationships, combined with our differentiated technology and service offerings, positions the Company to deliver long-term value for shareholders and stakeholders alike.As we move through 2026, we will be further improving the performance of our services segment. We are actively working with our largest customer toward a renewed and more sustainable contract structure, which we believe has the potential to materially enhance profitability and operating results over time." concluded Mr. Krakiwsky.Conference Call:Investors interested in participating in the live call can join through Zoom. Details provided below.https://us02web.zoom.us/j/88676886114?pwd=1Jl9AY8R4Cj6SdFA6DRxoIapgLGoir.1Meeting ID: 886 7688 6114Passcode: 439209One tap mobile+15074734847,,88676886114#,,,,*439209# USThe webcast will be archived on the Company's investor relations webpage for at least 90 days.Non-IFRS and Supplementary Financial MeasuresThe Company prepares and reports its consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, ?as adopted ?by the Canadian Accounting Standards Board ("IFRS"). However, this press release may make reference to certain non-IFRS measures including key ?performance indicators used by management. These measures are not recognized measures under IFRS ?and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable ?to similar measures presented by other companies. Rather, these measures are provided as additional ?information to complement those IFRS measures by providing further understanding of the Company's results of ?operations from management's perspective. Accordingly, these measures should not be considered in ?isolation nor as a substitute for analysis of the Company's financial information reported under IFRS.The ?Company uses Adjusted Earnings Before Interest, Tax, Depreciation and Amortization ("Adjusted EBITDA"), and Normalized net loss as non-IFRS measures, which may be calculated ?differently by other companies. These non-IFRS measure are used to provide investors supplemental measures of the Company's operating performance and liquidity and thus highlight trends in the Company's ?business that may not otherwise be apparent when relying solely on IFRS measures. The Company also ?believes that securities analysts, investors and other interested parties frequently use non-IFRS measures ?in the evaluation of companies in similar industries.Security services and flow through parts revenue

 Three months ended December 31 ($000's) 
20252024 ($) Change  Change Services revenue
5,5635,602(39)-1 %Services costs
4,9704,7312395 %Gross margin
593871(278) N/A 





Gross margin percentage
11 %16 %









 Three months ended December 31 ($000's) 
20252024 ($) Change  Change Flow-through inventory revenue  
9801,151(171)-15 %Flow-through inventory costs
9801,151(171)-15 %Gross margin
---








 Twelve months ended December 31 ($000's) 
20252024 ($) Change  Change Services revenue
22,14621,0101,1365 %Services costs
19,88018,4721,4088 %Gross margin
2,2662,538(272) N/A 





Gross margin percentage
10 %12 %









 Twelve months ended December 31 ($000's) 
20252024 ($) Change  Change Flow-through inventory revenue
4,5445,089(545)-11 %Flow-through inventory costs
4,5445,089(545)-11 %Gross margin
---
Adjusted EBITDA
 Three months ended December 31 ($000's) 20252024 ($) Change Net loss(729)(7,452)6,723Depreciation and amortization expense5691,086(517)Finance expense433293140Stock-based compensation90199(109)Other (income) expenses624124500Amortization of deferred wages2162151Loss from associate-345(345)Impairment of assets-7,052(7,052)Current income tax expense (recovery)(12)33(45)Deferred income tax (recovery) expense   (4)(60)56Adjusted EBITDA1,1871,835(648)




 Twelve months ended December 31 ($000's) 20252024 ($) Change Net loss(5,658)(13,613)7,955Depreciation and amortization expense3,4274,356(929)Finance expense 1,3671,34522Stock-based compensation4031,028(625)Other (income) expenses50643472Amortization of deferred wages839895(56)Loss from associate-1,085(1,085)Impairment of assets-7,326(7,326)Current income tax expense 54459Deferred income tax recovery(35)(67)32Adjusted EBITDA9032,834(1,931)Normalized net loss

 Three months ended December 31 ($000's) 
20252024 ($) Change Net loss
(729)(7,452)6,723Impairment of assets
-7,052(7,052)Normalized net loss   
(729)(400)(329)











 Twelve months ended December 31 ($000's) 
20252024 ($) Change Net loss
(5,658)(13,613)7,955Impairment of assets
-7,326(7,326)Normalized net loss
(5,658)(6,287)629Supplementary Financial Measures The Company may also use supplementary financial measures which are intended to be disclosed on a periodic basis to depict the historical or expected future financial performance, cash position, or cash flow of the Company, are not a non-IFRS measure, and are not presented in the financial statements. The measures as discussed in this press release include:Gross margin, which is defined as either product sales less cost of product sold, or, security services revenue less security services cost; and,Gross margin percentage, which is defined as either (product sales less cost of product sold) divided by product sales or (security services revenue less Security services costs) divided by security services revenueAbout Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:1N1)Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.Notice regarding Forward Looking Statements and Legal DisclaimerThis news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.



View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-announces-fourth-quarter-and-full-year-2025-results-302737360.htmlSOURCE Nanalysis Scientific Corp.

Original: Nanalysis Announces Fourth Quarter and Full Year 2025 Results

Nanalysis Announces Grant of Options and Restricted Share UnitsMarch 4, 2026 5:00 PM
PR Newswire (Canada)

CALGARY, AB, March 4, 2026 /CNW/ - Nanalysis Scientific Corp. (the "Company" or "Nanalysis") (TSXV: NSCI)  (FRA: 1N1) announces the Company's Board of Directors has granted 1,210,000 restricted share units ("RSUs") and 350,000 stock options ("Options") to certain directors, officers and employees of the Company, pursuant to the Company's stock option plan and restricted share unit plan (the "RSU Plan"), as applicable. Each Option is exercisable, once vested, to purchase one common share of the Company (a "Common Share") at $0.20 per share for a period of five years from the date of grant. Each vested RSU entitles the holder to receive one Common Share.







About Nanalysis Scientific Corp. (TSXV: NSCI, FRA: 1N1) Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.Notice regarding Forward Looking Information and Legal DisclaimerThis news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.



View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-announces-grant-of-options-and-restricted-share-units-302704398.htmlSOURCE Nanalysis Scientific Corp.

Original: Nanalysis Announces Grant of Options and Restricted Share Units

Nanalysis Announces Closing of Second Tranche to Complete its $3.4 Million OfferingJanuary 26, 2026 9:15 PM
PR Newswire (Canada)

CALGARY, AB, Jan. 26, 2026 /CNW/ - Nanalysis Scientific Corp. (the "Company" or "Nanalysis") (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) is pleased to announce, further to its December 8, 2025 and December 23, 2025 news releases, that it has closed the second and final tranche the ("Second Tranche") of its $3.4 million non-brokered private placement of units (the "Offering").







Under the Second Tranche, the Company has issued a total of 6,145,300 units (the "Units") at a price of $0.15 per Unit for additional gross proceeds of $921,795. In total, 22,671,583 Units have been issued pursuant to the Offering.Each Unit consists of one common share of the Company (a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder to acquire one additional Share at an exercise price of $0.20 per Share at any time up to 4:00 p.m. (Calgary time) on or before the date that is two years from the applicable closing date. The Warrants are subject to an acceleration provision whereby, if the closing price of the Shares on the TSX Venture Exchange equals or exceeds $0.30 for any 10 consecutive trading days, the Company may accelerate the expiry date of the Warrants to the date that is 30 days after the Company provides notice of or issues a press release announcing such acceleration.In connection with the second tranche of the Offering, the Company paid an aggregate of $2,000 in cash commission finder's fees to Leede Financial Inc. The Offering remains subject to final acceptance of the TSX Venture Exchange. All securities issued under the Offering are subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities laws.This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities, and there will be no sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.Notice regarding Forward Looking Information and Legal DisclaimerThis news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.



View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-announces-closing-of-second-tranche-to-complete-its-3-4-million-offering-302670319.htmlSOURCE Nanalysis Scientific Corp.

Original: Nanalysis Announces Closing of Second Tranche to Complete its $3.4 Million Offering

https://finance.yahoo.com/news/nanalysis-announces-change-management-130000261.html

Nanalysis Chosen by IMRIS as Critical Component MRI Supplier

https://nanalysis.investorroom.com/2025-09-03-Nanalysis-Chosen-by-IMRIS-as-Critical-Component-MRI-Supplier

CALGARY, AB, Sept. 3, 2025 /CNW/ - Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable Nuclear Magnetic Resonance (NMR) instruments and Magnetic Resonance Imaging (MRI) technology for industrial and research applications, has entered into a licensing agreement with IMRIS Imaging, Inc. ("IMRIS"). The Company and IMRIS have signed a multi-pronged five-year OEM supplier and technology licensing agreement, which includes an upfront payment and builds on a prior contract completed over the last 12 months.

"We are very proud of our relationship with IMRIS, a leader in intraoperative MRI that provides optimized, fully integrated operating suites that address the important needs of patients, clinicians, and hospitals," says Sean Krakiwsky, Nanalysis Scientific Corp. CEO. "The non-exclusive agreement we are announcing provides some immediate cash and some larger, medium-term revenue potential. The core electronics and software being licensed are also used in our benchtop NMR and high-field NMR products, which are sold around the world. This deal is emblematic of how our MRI and NMR businesses reinforce one another to create scalable, global growth opportunities. "

Nanalysis CTO, Julien Muller, says: "My vision has been to develop a technology platform that is feasible for benchtop NMR, high-field NMR and MRI. The fundamental math and physics are largely the same across many types of magnetic resonance applications, and value is optimized by adopting such a strategy. This deal validates our technology platform strategy of leveraging our core electronics and software for different types of magnetic resonance applications where image quality and speed are paramount. We have been working with IMRIS for about a year and with their magnet subsidiary for over a decade. We are excited about our future together."

Marc Buntaine, IMRIS CEO, states, "We have a very rigorous process to vet critical component suppliers and have been very impressed by Julien and the Nanalysis team. Their MRI console has allowed us to be successful during system prototyping, and we are confident that Nanalysis Scientific Corp. is the right partner as we continue development and progress toward commercialization."

About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:1N1)

Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.

About IMRIS Imaging, Inc.

As a leader in image guidance solutions, IMRIS Imaging, Inc., provides optimized, fully integrated image-guided therapy environments that address the important needs of patients, clinicians, and hospitals by delivering timely MRI and imaging data to clinicians for use during surgical or interventional procedures. The IMRIS Operating Suite enables intraoperative imaging directly within operating rooms. IMRIS also designs and manufactures proprietary head fixation devices, imaging coils and OR tables for use in this unique and multifunctional intraoperative environment. IMRIS products are sold globally to clinical centers in the neurosurgical, spinal, cardiovascular and orthopedic markets. It is estimated that over 70,000 patients have benefited from lifesaving or life-extending procedures performed in an IMRIS Operating Suite. Additional information about IMRIS is available at www.imris.com.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE Nanalysis Scientific Corp.

Nanalysis Announces Second Quarter 2025 Conference Call



Hosting Call at 5:00 pm ET on Thursday, August 28th

European Q&A Session on Friday, August 29th at 8:30am ET


CALGARY, AB, Aug. 21, 2025 /CNW/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR instruments and imaging technology and services for industrial and research applications announces that on Thursday, August 28th, 2025, the Company will put out a press release and Chief Executive Officer Sean Krakiwsky and Chief Financial Officer Randall McRae will host a conference call at 5:00 P.M. Eastern Time to discuss the results for the quarter ended June 30, 2025.


Investors interested in participating in the live call can dial 1-437-900-0527 or 1-888-510-2154 from abroad. Investors can also access the call online through a listen-only webcast here: https://app.webinar.net/qrKemn9Rxv0 or on the investor relations section of the Company's website HERE.
https://nanalysis.us20.list-manage.com/track/click?u=47f66af4f730e799151531b55&id=6a604fb0e7&e=224cbcf3b3


The webcast will be archived on the Company's investor relations webpage for at least 90 days, and a telephonic playback will be available for seven days after the conference call by calling 1-888-660-6345 or 1-289-819-1450, conference ID # 83432.


Additionally, the Company will be hosting a Q&A session for its European investors at 8:30am ET on Friday, August 29th which can be accessed by the following link (Join the meeting now):
https://nanalysis.us20.list-manage.com/track/click?u=47f66af4f730e799151531b55&id=d41f096ef4&e=224cbcf3b3

Kind of disappointing Q1 release. Blaming macro-economics is not a good sign for small high growth companies, even if it would be the case. Especially the CATSA margins declined unexpectedly, vs. Q4., no revenue growth, unattractive forecast. Will stay in, but seems to become another lost year

https://finance.yahoo.com/news/nanalysis-announces-fourth-quarter-full-200500868.html

I asked the company about this revenue, if there is some margin to be earned on this.

"In terms of your question, the margin on this flow through, or parts business is really nominal or non-existent. That was one of the reasons why we wanted to break it out. Now we do make margin on servicing in relation to these parts which would be in our regular disclosed service margins."

Accounting wise it has to be declared as revenue. but as they don't earn on that revenue they set it separate, which makes sense to me.

Translation from a publication by Safecapital in Belgium
Yesterday after-hours, Nanalysis announced its results for the first quarter of this year. Despite still making a loss, the results improved once again. A record revenue of CAD 11.2 million was made, 139% higher than the same period last year.
Normally the fourth quarter is a lot better than the first quarter, but this quarter was very good. Security Services revenue (CATSA contract) continued to increase, and lower costs resulted in a positive EBITDA margin of 8% ( 21% negative the previous quarter).
A milestone for the company, in other words. The huge job is on its way, all 89 airports are fully up and running, and costs have fallen sharply. Nanalysis expects to get even more revenue from this and improve efficiency. As of now, they can start reaping the benefits of the tremendous efforts.
Sales from benchtop NMRs were also high, especially compared to the previous year, and Sean sees this strength continuing. Sales from Product Sales (which includes benchtop NMRs) were 39% higher than the year before, and the gross margin of 47% was a lot higher than the 32% of 2023.
Finally, EBITDA for the entire company was still negative at CAD 362,000, but this has declined sharply. In Q2 last year it was still negative by CAD 2.4 million, negative by CAD 1.3 million in Q3, and negative by CAD 774,000 in Q4. So the upward trend is clearly visible!

The share price had briefly decreased to the low point of below 0.36 CAD after the share issue announcement in February. Since then, the share price has rebounded and has been trading around 0.45 CAD for a few weeks. With excellent quarterly earnings and profitability on the horizon, we expect a higher share price.
Conclusion: Once again good quarterly rzvznuz figures from Nanalysis. The company is well on its way to becoming profitable this year. In addition, there are other opportunities to expand their sales. Therefore, the future looks bright for Nanalysis. With that comes a higher share price.

Translated with DeepL.com (free version)

Results do show they are heading into a better direction. Gross margin on Airport service part seems still low and should improve further. I don't like that they account procurement related services on behalf of their customer with zero-margin as revenue. Revenue of NMR's keeps on developing positively after the big dip some time ago.

https://nanalysis.investorroom.com/2024-05-29-Nanalysis-Announces-First-Quarter-2024-Results

The CEO of Nanalysis gave a very promising presentation in Antwerp and Ghent. FOCUS will now be on profitability instead of acquisitions. No acquisitions nor dilutive PP anymore below Cad 3. looking forward for next conference call.

Added some this week after that news. Company is severely undervalued and under the radar. Bright future ahead. Once peeps catch on, it will gain traction.

I have the report on my computer at home but am on holiday in Spain. The report was dated february 6.

ask IR

Some extra publicity around the succes is always useful. Do you know any site or source that contains their recommondation (that isn't behind a paywall)?

Echelon wrote a new report. price target 1.40

--> -->

They are indeed back on track


Dear Investor,
 

Nanalysis Achieves Record Revenue in Q4

 
 
CALGARY, AB, February 6, 2024 Nanalysis Scientific Corp. (“the Company” or “Nanalysis”, TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR machines, MRI technology for industrial and research applications, and detection equipment services, provides an estimate of Q4 2023 unaudited revenue and highlights some other recent business accomplishments.
 
Sean Krakiwsky, Founder and CEO of Nanalysis, states: “We are very pleased with how the fourth quarter closed out 2023, a year not without its challenges.  While our Security Services business continued its ramp through the end of the year, we also had strong results in our benchtop sales that we expect to continue into the first quarter. With both Benchtop NMR and Security Services contributing significantly, we were able to achieve fourth quarter unaudited revenues of between $9.3MM and $9.8MM, constituting a new record quarter for Nanalysis.”[1]
 
“We feel that with the continued trajectory of the Company’s airport security maintenance project, returning strength to Benchtop NMR revenue, and our cost cutting measures that were implemented last year and continuing into 2024, we are making progress toward our corporate objective of generating positive EBITDA in this fiscal year.”
 
Financial and Operational Highlights:
 

New Quarterly Revenue Record: Q4 2023 revenue will be at least $9.3MM (unaudited), driven by continued expansion of security services related to the Company’s airport security maintenance project, as well as continued recovery in Benchtop NMR sales.   Phase-In of the Company’s Airport Security Maintenance Project:  On January 11, 2024, the Company completed the phase-in period related to its airport security maintenance project, resulting in the Company’s Security Services business now performing maintenance of passenger screening imaging and detection equipment across all of Canada. We are confident that the highly capable team we’ve built during this project will provide significant growth opportunities for this business with new customers and partners.   100 MHz Benchtop NMR Product:  In Q4, the Company sold and shipped 14 100MHz Benchtop NMR units, the highest number of shipments for 100 MHz units in a quarter since the Company cleared its backlog in 2022. This drove continued recovery in Benchtop NMR revenue.   Customer satisfaction is high, and we continue to seek value added partnerships and new software applications to drive more growth.   New Patent Grant: The Company expanded its patent portfolio with the grant of United States Patent #US 11,815,574B2 which is part of the ongoing patent pipeline for its Benchtop NMR products.  The Company continues to innovate in several areas of magnetic resonance technology, and we are proud of this recent patent grant directly associated with the 100 MHz product.  
About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1)
 
Nanalysis Scientific Corp. operates two primary businesses: Scientific Equipment and Security Services. Within its Scientific Equipment business is what the Company terms "MRI and NMR for industry". The Company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The Company has followed-up that initial offering with new products and continues to have a strong innovation pipeline. In 2020, the Company announced the launch of its 100MHz device, the most powerful and most advanced compact NMR device ever brought to market.
 
The Company’s devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners.  With its partners, the Company provides scientific equipment sales and maintenance services globally.
 
In 2022, through its subsidiary KPrime, the Company was awarded a five-year, $160 million contract with the Government of Canada to provide maintenance services for passenger screening equipment in Canadian airports.  This has resulted in the expansion of the Company’s Security Services business.  The Company is providing airport security equipment maintenance services for the Government of Canada in each province and territory of Canada.  In addition, the Company provides commercial security equipment installation and maintenance services to a variety of customers in North America.
 
Notice regarding Forward Looking Statements and Legal Disclaimer
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

 

[1] All figures and results referenced in this press release are preliminary and unaudited

 

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Matthew Selinger
Firm IR Group
415-572-8152
mselinger@firmirgroup.com or matthew.selinger@nanalysis.com

 

View this email in your browser Copyright © 2020 Nanalysis Scientific Corp., All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list. --> -->

they will be back on track.

Nanalysis Scientific Corp. Provides Update on Security Services Business

Phase-In of Canada-Wide Coverage at All 89 Designated Airports Completed on January 11, 2024


CALGARY, AB, January 30, 2024 Nanalysis Scientific Corp. (“the Company” or “Nanalysis”, TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR machines, MRI technology for industrial and research applications, and detection equipment services, gives an update on its subsidiary K’(Prime) Technologies (“KPrime”) security services business and the five-year $160 million contract with Canadian Air Transport Security Authority (“CATSA”).

Completion of the CATSA Project Rollout

Sean Krakiwsky, Founder and CEO of Nanalysis, states: “With the announcement of the award of the CATSA contract back in May of 2022 to the Company’s subsidiary KPrime, we significantly expanded our Security Services business, which, over time, will increase our capability to support our proprietary products in NMR and MRI technology. At the time of the award, we announced that there was an initial phase-in period for the project. This period involved our team hiring and training over 100 technicians and taking over all preventative and corrective maintenance services for passenger screening equipment at 89 airports in Canada from the incumbent service provider. We are happy to report we are through that phase-in period and are now in control of the basic service and maintenance of all 89 airports in Canada. The focus now is to start working on the backlog of additional projects and requirements that CATSA has for us. We will do this with the same workforce, and therefore, we are in a phase of the contract whereby the costs level off and revenue is expected to increase substantially.”

“Having now taken over all preventative and corrective maintenance services for CATSA, we expect the project to begin generating positive EBITDA in Q1 2024*. As fixed costs have flattened while revenues are ramping up, I expect to maximize EBITDA throughout 2024 and for years to come.”

Denis Perron, Senior Director, Screening Technology at CATSA, states: “We have been very pleased with KPrime’s progress and congratulate them on achieving this important milestone through their ongoing commitment to building a very capable service team across Canada.”

Sime Buric, President of KPrime, a subsidiary of Nanalysis, states: “I am very proud of everyone within the organization that worked tirelessly on this project. The team has been hard at work, in collaboration with CATSA, CATSA’s equipment manufacturers, and the exiting incumbent service provider, to reach this major milestone. The team is adaptive and continuously looks for improvements. This approach will position us to expand the capabilities and opportunities for our Security Services business with other customers and partners.”

Project Highlights:

*Project EBITDA: As of January 2024, with the phase-in period's completion, the project is expected to generate positive EBITDA in Q1 2024, excluding final one-time training costs which will end March 31, 2024. EBITDA is expected to grow through 2024 and provide a stepped-up EBITDA contribution for the rest of the contract. Please see the note below regarding one-time and ongoing training obligations.

Fully Executed Cutover Plan as of January 11, 2024: As a result of the hard and relentless work of the KPrime leadership team and local technicians, and with the support of CATSA’s equipment manufacturers and the incumbent service provider, KPrime has now assumed all maintenance responsibilities for CATSA’s fleet of imaging and detection equipment across all of Canada.

Canada-Wide Coverage: KPrime now performs maintenance of CATSA imaging and detection equipment at all 89 designated airports and is now also providing additional authorized work support to CATSA.

Training costs: Initial training costs for staff maintenance certifications were substantial in the phase-in period. While the Company has taken over all 89 airports, it is still expecting some initial training to occur in the first quarter of 2024 for its most recently hired team members. After completion of initial training, the Company expects lower ongoing training costs commensurate with ordinary staff turnover and ongoing certification maintenance.


About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1)

Nanalysis Scientific Corp. operates two primary businesses: Scientific Equipment and Security Services. Within its Scientific Equipment business is what the Company terms "MRI and NMR for industry". The Company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The Company has followed-up that initial offering with new products and continues to have a strong innovation pipeline. In 2020, the Company announced the launch of its 100MHz device, the most powerful and most advanced compact NMR device ever brought to market.

The Company’s devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market
opportunities independently and with partners. With its partners, the Company provides scientific equipment sales and maintenance services globally.

In 2022, through its subsidiary KPrime, the Company was awarded a five-year, $160 million contract with CATSA to provide maintenance services for passenger screening equipment in Canadian airports. This has resulted in the expansion of the Company’s Security Services business. The Company is providing airport security equipment maintenance services for CATSA in each province and territory of Canada. In addition, the Company provides commercial security equipment installation and maintenance services to a variety of customers in North America.


Notice regarding Forward Looking Statements and Legal Disclaimer
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.


For further information, please contact:

Matthew Selinger
Firm IR Group
415-572-8152
mselinger@firmirgroup.com or matthew.selinger@nanalysis.com



View this email in your browser
Copyright © 2020 Nanalysis Scientific Corp., All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
Twitter
Facebook
Website

https://nanalysis.investorroom.com/2023-08-15-Nanalysis-Announces-Second-Quarter-2023-Conference-Call

Absolutely worth to look at. This company is wildly undervalued.

Watch the coming months when the Catsa contract is going to bringin a lot of cash

Disappointing last quarter, but Catsa seems even better than thought and some cost saving measures in place. Buy the dip?
Yes, I did so last Friday.

Hi Walter,

Any new thoughts about the results?

thx

Thanks for the update walterc

Thanks Walter,

So we just have to be patient,

grtz,

EXtract from a report which I write to my Belgian and Dutch friends on my startup investments ( computertranslated from Dutch)

NANALYSIS ( TU QUOQUE FILI MI)

This famous statement in history applies here as well. I did not expect that we also had to wait a bit longer for positive results at Nanalysis. Hence probably the increasingly lower share prices over the last few months.
Those who wondered how a company that only 2 years ago had a turnover of CAD 8 million per year and then suddenly won a government contract (CATSA) of CAD 160 million over the next 5 years (with a chance of extension) could be doing so poorly on the stock market at the moment were given the answer on Thursday evening's cc and Friday afternoon's cc as well. The CATSA contract was delayed and had also weighed on the other business segments . Recruiting and training over 100 people in a very short period of time turned out to be a little more intense than planned . CEO Sean admitted that he had underestimated the situation.

The positive news is that the contract is now up and running and the government is very pleased with the service Nanalysis is providing. At the moment, they have started in 39 of the 80 airports in Canada...The roll-in period is now mostly over and it is expected that revenues will increase each quarter as more airports are served. The roll-in period for each airport has also been greatly reduced by the experience gained.
Without the Catsa contract, Nanalysis probably would already have shown positive results this last quarter. However, the Catsa contract suddenly crossed their way and then a decison had tob e made do we do it or don't we do it?.
It had long been a goal to establish a major service arm in Nanalysis so this was the time . With the Catsca contract renewable after 5 years, Nanalysis is going to have a stable cash inflow in the coming years and they could notjust miss that opportunity.. Moreover, this contract is a catalyst for other service contracts with public companies in other countries.
The total direct walk-in cost for the Catsa contract was estimated at a CAD 3.8 million . I would have preferred those to be capitalized on the balance sheet and be amortized over the life of the Catsa contract but that appears to be against international accounting rules. Still, that would have seemed more logical to me.
Nanalysis also had to deal with staff turnover in the sales department this year when they wanted to change the compensation of salespeople where now salespeople are rewarded more based on their successes. Some former salespeople who didn’t accept that change left the company and that of course affected sales. This problem is now behind us.
Also the launch of the 100 MGHZ devices gave some run-in problems where the first shipments were recalled and repaired which meant a cost of 260K cad. This has also been resolved.
The reduction in the gross margin is a resultof a mix of all these start up - problems but also because some sales by Kprime of third-party products yield only a commission and not sales revenue. After the run-in period, that gross margin will go back toward 60+ percent.
In the second half of this year, Nanalysis should become clearly cash flow positive.

For this reason, the price target for Nanalysis in the Echelon report is not unreasonable. Nanalysis Scientific is undervalued, says Echelon - Cantech Letter

this report was made before the conference call but gives already some flavour
https://www.cantechletter.com/2023/04/nanalysis-scientific-is-undervalued-says-echelon-2/amp/

Thanks Walter,
But i feel a little disappointed about the outlook given by the company, as an investor
it is a little inaccurate, they do not often give news about sales or contracts either.(ex cats)
I own the stock a couple of years now because i believe in the compact technology.
I know that you always have a clear look on what's happening here, that's why i ask your
opinion,

grtz and thanks

I will make some more detailed report over the weekend after i will listen again to the cc.

The future potential remains intact.
Catsca deal will be very rewarding but was a roadblock for the short term performance

Hi Walter,

What do you think about the results now?

grtz

https://nanalysis.investorroom.com/2023-04-18-Nanalysis-and-QUAD-Systems-Launch-Full-400MHz-High-Field-System

This site mentions that the report date is April 27, 2023 (Not Confirmed).

https://www.tipranks.com/stocks/nscif/earnings

When is Q4 report date? Anyone knows?

Trying to buy Nanalysis at 0.66
Ask: 0.68x500
Bid: 0.65x8,000

I do not know many companies like Nanalysis that can double in revenue year after year.

Nanalysis has a great potential but it's not on the right exchange yet. Lack of interest and lack of volume is killing it. Sean talked already about uplisting, but we have to be patient for that.
2-3 years ago NSCI only had revenue for about 6-8 milllion. Now they have a contract with the Canadian Governement for +/- 150 million.
If you have some dry powder, maybe it can be an opportunity to add some shares at these prices. Future should louk bright.

Any reason published for this steep correction?

3X Your Money in 2023 with Nanalysis

https://medium.com/right-way-investing/3x-your-money-in-2023-with-nanalysis-b73afaf92fb8

Nanalysis Scientific Corp.
Pre-Announced Q3 Revenues Beat Expectations, Growth Trajectory
Back on Track After Tough Q2; Maintaining Buy Rating, $2.75 PT

Nanalysis Scientific Sets Q3 Outlook
10/20/2022 | 09:41am EDT

(MT Newswires) -- Nanalysis Scientific (NSCI.V), a provider of portable NMR machines and MRI technology for healthcare and industrial applications, said Thursday that it is expecting gross revenue of nearly $6.8 million for the third quarter.

This represents an increase of more than 100% year over year.

The company's shares remained unchanged on last look on Thursday.


© MT Newswires 2022

100 percent correct. The future of this company looks bright.

I considered it Can$ being it a Canadian company with Canadian listing.
Next months might offer opportunities to buy cheaper, but midterm and longer term should show positive and strong share price development.

I saw the same presentation in Ghent. When i was thinking about his estimates (not official guidance btw), I was in doubt if those numbers were CAD or USD $?

All in in all a very positive presentation, executing on their plan as promised.
Technical trend is downward and market sentiment is terrible, so it is very well possible you'll be able to scoop some up at bargain prices in the coming months.

Yes a little unfortunate as the company was, is and will be extremely interesting. Sean Krakiwsky made a very interesting presentation in Mechelen lately. Illustrated revenue for FY23 between 48 and 77 million as CATSA (Security Service). CATSA (security services) will start generating solid and significant revenue with attractive EBITDA. Keep this share the next 5 years and you won't be disappointed. At least I will do.